Your browser doesn't support javascript.
loading
Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD.
Inamoto, Y; Jagasia, M; Wood, W A; Pidala, J; Palmer, J; Khera, N; Weisdorf, D; Carpenter, P A; Flowers, M E D; Jacobsohn, D; Martin, P J; Lee, S J; Pavletic, S Z.
Affiliation
  • Inamoto Y; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Jagasia M; Hematology and Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wood WA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Pidala J; Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Palmer J; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Khera N; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
  • Weisdorf D; Blood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
  • Carpenter PA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Flowers ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Jacobsohn D; Division of Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC, USA.
  • Martin PJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Lee SJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Pavletic SZ; National Cancer Institute, Bethesda, MD, USA.
Bone Marrow Transplant ; 49(4): 532-8, 2014 Apr.
Article in En | MEDLINE | ID: mdl-24464142
ABSTRACT
The 2005 National Institutes of Health (NIH) consensus criteria for chronic GVHD have set standards for reporting. Many questions, however, have arisen regarding their implementation and utilization. To identify perceived areas of controversy, we conducted an international survey on diagnosis and scoring of chronic GVHD. Agreement was observed for 50-83% of the 72 questions in 7 topic areas. There was agreement on the need for modifying criteria in six situations two or more distinctive manifestations should be enough to diagnose chronic GVHD; symptoms that are not due to chronic GVHD should be scored differently; active disease and fixed deficits should be distinguished; a minimum threshold body surface area of hidebound skin involvement should be required for a skin score of 3; asymptomatic oral lichenoid changes should be considered a score 1; and lung biopsy should be unnecessary to diagnose chronic GVHD in a patient with bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of controversy. Whenever possible, studies should be conducted to confirm the appropriateness of any revisions. In cases where data are not available, clarification of the NIH recommendations by consensus is necessary. This survey should inform future research in the field and revisions of the current consensus criteria.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graft vs Host Disease Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2014 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graft vs Host Disease Type of study: Diagnostic_studies / Guideline / Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2014 Document type: Article Affiliation country: United States
...